Cipla

OverviewSuggest Edit

Cipla is a global pharmaceutical company, which offers active pharmaceutical ingredients and formulations in various therapeutic areas, such as women’s health, cardiovascular, children’s health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The Company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals.

TypePublic
Founded1935
HQMumbai, IN
Websitecipla.com
Employee Ratings3.9
Overall CultureA+

Latest Updates

Employees (est.) (Apr 2018)23,043
Job Openings58
Revenue (FY, 2022)₹216.2 B(+14%)
Share Price (Jun 2022)₹933.7
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Cipla

Umang Vohra

Umang Vohra

Managing Director & Global Chief Executive Officer
Y. K. Hamied

Y. K. Hamied

Chairman
Kedar Upadhye

Kedar Upadhye

Global Chief Financial Officer
Philippe Malecki

Philippe Malecki

Regional Head APAC
Anchal Sultania

Anchal Sultania

Business Head - Europe and Russia CIS
Anand Agarwal

Anand Agarwal

Regional Head - MEPAC
Show more

Cipla Office Locations

Cipla has offices in Mumbai, Central Islip, South Melbourne, Nairobi and in 7 other locations
Mumbai, IN (HQ)
1, Peninsula Spenta, Mathuradas Mill Compound, Senapati Bapat Marg, Lower Parel
Mumbai, IN
2nd Floor, Bldg, 5, LBS Rd, Suryanagar No. 2, HMPL Surya Nagar, Vikhroli West
South Melbourne, AU
Level 1/132 Albert Rd
Nairobi, KE
Chiromo Road Purshottam Place
Cape Town, ZA
Mispel Street, Bellville
Durban, ZA
18 The Boulevard, Westway Office Park, Dawncliffe
Show all (13)

Cipla Financials and Metrics

Cipla Revenue

Cipla's revenue was reported to be ₹216.23 b in FY, 2022
INR

Revenue (FY, 2022)

216.2b

Gross profit (FY, 2022)

135.5b

Net income (FY, 2022)

25.6b

EBITDA (FY, 2022)

48.3b

EBIT (FY, 2022)

36.0b

Market capitalization (24-Jun-2022)

758.3b

Closing stock price (24-Jun-2022)

933.7

Cash (31-Mar-2022)

19.3b

EV

749.6b
Cipla's current market capitalization is ₹758.3 b.
INRFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022

Revenue

146.9b159.7b166.9b189.9b216.2b

Cost of goods sold

(54.4b)(57.8b)(59.9b)(73.5b)(85.0b)

Gross profit

98.2b106.7b111.8b118.9b135.5b
INRFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022

Cash

9.7b6.2b10.0b14.0b19.3b

Accounts Receivable

31.0b41.5b38.9b34.5b34.2b

Prepaid Expenses

2.7b3.0b2.8b2.8b

Inventories

40.4b39.6b43.8b46.7b53.5b
INRFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022

Net Income

16.7b20.8b21.8b32.9b36.8b

Depreciation and Amortization

9.5b11.0b10.0b9.1b10.5b

Inventories

(5.6b)1.0b(3.3b)(2.5b)(6.2b)
INRFY, 2018

Revenue/Employee

6.4m
Show all financial metrics

Cipla Revenue Breakdown

Embed Graph

Cipla revenue breakdown by business segment: 98.1% from PHARMACEUTICAL and 1.9% from Other

Cipla Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

SecurityScorecard logo

Cipla Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Cipla Online and Social Media Presence

Embed Graph

Cipla Company Culture

  • Overall Culture

    A+

    83/100

  • CEO Rating

    F

    10/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Cipla News and Updates

Stocks To Watch Today: Adani Wilmar, Axis Bank, Cipla, Delhivery, ICICI Bank, Yes Bank

Here are the stocks to watch going into trade today.

Cipla To Acquire 21% Stake In Achira Labs For Rs 25 Crore

The company has signed definitive agreements with Achira Labs for the purpose, Cipla said in a regulatory filing.

Marico To Cipla, Morgan Stanley’s Views On India Stocks

Morgan Stanley hosted its ‘Virtual India Summit’ on June 7-9 in Mumbai.

Bharti Airtel, Cipla, Tech Mahindra And More - Top Stock Picks For June By Axis Securities

Bharti Airtel, Cipla, Tech Mahindra And More - Top Stock Picks For June By Axis Securities

Global Intestinal Pseudo Obstruction Treatment Market Report 2022-2027 Featuring Pfizer, Cipla, GlaxoSmithKline, Teva., Eli Lilly and Co, Novartis, J&J, Dr. Reddy's Lab, F. Hoffmann-La Roche, Lupin

DUBLIN, May 20, 2022 /PRNewswire/ -- The "Global Intestinal Pseudo Obstruction Treatment Market, By Condition (Acute v/s Chronic), By Diagnosis (Physical Examination, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Others), By Treatment, By End User, By Region, Competitional...

Cipla - Multiple Triggers In Place; Execution Is Key: Dolat Capital

Cipla - Multiple Triggers In Place; Execution Is Key: Dolat Capital
Show more

Cipla Blogs

Humane Approach To Health Care

It’s been a week of accolades for scientist and chairman of Cipla, Dr Yusuf K Hamied, who received the Indore Management Association Lifetime Achievement Award for 2018 last Friday. “It was attended by 5,000 management students and 1,000 business executives, and was really quite impressive,” he said…

Patents and patients

Of patents and patients Pharmaceutical giant Cipla’s archive is worth emulating for all legacy companies. This diarist toured it last week and was surprised to see the effort gone into chronicling the company’s eight-decade-long journey. A visitors’ book from 1939, signed by both Mahatma Gandhi and …

Of Patents and Patients

Pharmaceutical giant Cipla’s archive is worth emulating for all legacy companies. This diarist toured it last week and was surprised to see the effort gone into chronicling the company’s eight-decade-long journey. A visitors’ book from 1939, signed by both Mahatma Gandhi and Sardar Vallabhbhai Patel…

In Remote Villages, Surprising New Measures Save Children With Malaria

Malaria quickly kills toddlers. But rapid diagnostic tests, a new suppository drug and bicycle ambulances can buy enough time to get stricken children to hospitals. During malaria season, children who live in remote villages are at tremendous risk. When parasites transmitted by mosquitoes swarm into…

A first in Morocco: CIPLA MAROC opens an inhaler manufacturing plant in the Rabat region for an investment of 60 MDH

Inaugurated by MM. Anas Doukali and MM. Moulay Hafid Elalamy, the plant will produce 1.5 million metered-dose inhalers annually Rabat, Morocco, October 13, 2018: Cipla Maroc, subsidiary of the leading global pharmaceutical company Cipla Ltd, today announced the official opening of its manufacturing …

Guardian story on RAS

Internally administered medicine allows crucial window of time for children in remote areas to reach healthcare facilities A suppository form of a malaria-fighting drug could provide a lifeline to children in rural areas, drastically cutting the number of deaths caused by the disease. A study in rur…
Show more

Cipla Frequently Asked Questions

  • When was Cipla founded?

    Cipla was founded in 1935.

  • Who are Cipla key executives?

    Cipla's key executives are Umang Vohra, Y. K. Hamied and Kedar Upadhye.

  • How many employees does Cipla have?

    Cipla has 23,043 employees.

  • What is Cipla revenue?

    Latest Cipla annual revenue is ₹216.2 b.

  • What is Cipla revenue per employee?

    Latest Cipla revenue per employee is ₹9.4 m.

  • Who are Cipla competitors?

    Competitors of Cipla include Biocon, Abbott India and Pfizer.

  • Where is Cipla headquarters?

    Cipla headquarters is located at 1, Peninsula Spenta, Mathuradas Mill Compound, Senapati Bapat Marg, Lower Parel, Mumbai.

  • Where are Cipla offices?

    Cipla has offices in Mumbai, Central Islip, South Melbourne, Nairobi and in 7 other locations.

  • How many offices does Cipla have?

    Cipla has 13 offices.